好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Early and 30-day Clinical and Neuropsychological Effects of Iatrogenic Brain Infarcts in the ENACT Randomized-Controlled Trial
Cerebrovascular Disease and Interventional Neurology
P1 - Poster Session 1 (9:00 AM-5:00 PM)
087

To examine the association of iatrogenic brain infarcts with patient outcomes

Small iatrogenic brain infarcts are often seen on diffusion-weighted MRI (DWI) following surgical or endovascular procedures, but there are few data on their clinical effects. We examined the association of iatrogenic infarcts with outcomes in the ENACT(Evaluating Neuroprotection in Aneurysm Coiling Therapy, NCT00728182) randomized-controlled trial of nerinetide in patients undergoing endovascular repair of intracranial aneurysms.

In this post-hoc analysis, we used multi-variable models to evaluate the association of the presence and number of iatrogenic infarcts on DWI with neurological impairment (National Institutes of Health Stroke Scale[NIHSS]), functional status (modified Rankin Scale[mRS]), cognitive and neuropsychiatric outcomes (30-minute test battery) at 1-4 days and 30-days post-procedure. We also related infarct number to a Z-score-derived composite outcome score using quantile regression.

Among 184 patients (median age 56,IQR:50-64), 124 (67.4%) had post-procedural DWI lesions (median 4,IQR:2-10.5). Nerinetide treatment was associated with fewer iatrogenic infarcts but no overall significant clinical treatment effects. Patients with infarcts had lower Mini-Mental State Exam(MMSE) scores at 2-4 days (median:28 vs 29, adjusted-coefficient[acoef]:-1.11, 95%CI:-1.88 to -0.34,p=0.005). Higher lesion counts were associated with worse day-1 NIHSS (aOR for NIHSS≥1:1.07, 1.02-1.12,p=0.009), day 2-4 mRS (adjusted common odds-ratio[aOR]:1.05,1.01-1.09,p=0.005), and day 2-4 MMSE (acoef:-0.07,-0.13 to -0.003,p=0.040) scores. At 30-days, infarct number remained associated with worse mRS (aOR:1.04,1.01-1.07,p=0.016) and Hopkins Verbal Learning Test(HVLT) delayed-recall scores (acoef:-0.21,-0.39 to -0.03,p=0.020). Higher lesion count was associated with worse composite outcome scores at both 1-4 days and 30-days (30-days acoef:-0.12,-0.21 to -0.03,p=0.008). Among those with infarcts, day-1 NIHSS and day 2-4 mRS correlated with 30-day NIHSS, HVLT, and mRS scores, whilst day 2-4 MMSE correlated with 30-day NIHSS scores (Spearman-Rho:0.47,p=0.001).

Iatrogenic brain infarcts were associated with subtle differences in post-procedural(1-4 days) and 30-day outcomes on different measures in this middle-aged cohort, with earlier dysfunction correlating with later differences.

Authors/Disclosures
Aravind Ganesh, MD (Department of Clinical Neurosciences, University of Calgary)
PRESENTER
Dr. Ganesh has received personal compensation in the range of $0-$499 for serving as a Consultant for Figure 1. Dr. Ganesh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier Canada. Dr. Ganesh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Ganesh has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Ganesh has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Let's Get Proof (Collavidence Inc). Dr. Ganesh has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for 好色先生 (journals Neurology and Neurology: Clinical Practice). Dr. Ganesh has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association (journal: Stroke). Dr. Ganesh has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers (for Frontiers in Neurology). Dr. Ganesh has or had stock in SnapDx.Dr. Ganesh has or had stock in Collavidence Inc.Dr. Ganesh has or had stock in DataSimpl. The institution of Dr. Ganesh has received research support from Canadian Institutes of Health Research . The institution of Dr. Ganesh has received research support from Alberta Innovates. The institution of Dr. Ganesh has received research support from University of Calgary Centre for Clinical Research. The institution of Dr. Ganesh has received research support from Innovation 4 Health. The institution of Dr. Ganesh has received research support from Government of Canada INOVAIT. The institution of Dr. Ganesh has received research support from Campus Alberta Neuroscience. The institution of Dr. Ganesh has received research support from Alzheimer Society of Canada. The institution of Dr. Ganesh has received research support from Heart and Stroke Foundation of Canada. The institution of Dr. Ganesh has received research support from New Frontiers in Research Fund. The institution of Dr. Ganesh has received research support from Panmure House. The institution of Dr. Ganesh has received research support from Brain Canada. The institution of Dr. Ganesh has received research support from MSI Foundation. The institution of Dr. Ganesh has received research support from France Canada Research Fund. Dr. Ganesh has received intellectual property interests from a discovery or technology relating to health care.
Mayank Goyal, MD, PhD No disclosure on file
No disclosure on file
Johanna Ospel No disclosure on file
Andrew M. Demchuk, MD (Foothills Hospital/Calgary Stroke Program) Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lumosa. Dr. Demchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Pfizer/BMS. Dr. Demchuk has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Boehringer Ingelheim. Dr. Demchuk has received stock or an ownership interest from Circle NVI. Dr. Demchuk has received intellectual property interests from a discovery or technology relating to health care.
David J. Mikulis, MD (Toronto Hosp Western Div) Dr. Mikulis has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Neinstein Personal Injury Lawyers. Dr. Mikulis has received stock or an ownership interest from Thornhill Medical, Inc.. Dr. Mikulis has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
No disclosure on file
No disclosure on file
Michael Tymianski, MD, PhD, FRCSC Michael Tymianski, MD, PHD, FRCSC has received personal compensation for serving as an employee of NoNO Inc.. Michael Tymianski, MD, PHD, FRCSC has stock in NoNO Inc.
Michael D. Hill, MD (University of Calgary) Dr. Hill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Dr. Hill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sun Pharma. Dr. Hill has received stock or an ownership interest from Circle Neurovascular.